{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.57","upperLimit":"0.78","value":"0.69"},{"groupId":"OG001","lowerLimit":"0.46","upperLimit":"0.79","value":"0.70"},{"comment":"upper limit could not be estimated due to insufficient number of events.","groupId":"OG002","lowerLimit":"0.021","upperLimit":"NA","value":"0.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"The landmark analysis for 6 month rPFS rate will occur when all participants on Part 1 have been on study for at least 6 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"NUMBER","populationDescription":"All participants according to the study treatment assigned (Intent to Treat Population) for participants with mCRPC in Part 1 only. This outcome measure applies to Part 1 only. Per protocol, participants in Part 2 did not have mCRPC and were not part of this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every 8 weeks for six months. Six month data reported.","title":"Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator","type":"PRIMARY","unitOfMeasure":"proportion of participants"}